Literature DB >> 11038285

Determination of matrix metalloproteinase activity using biotinylated gelatin.

B Ratnikov1, E Deryugina, J Leng, G Marchenko, D Dembrow, A Strongin.   

Abstract

Matrix metalloproteinases (MMPs) and, specifically, MMP-2 (gelatinase A) and MMP-9 (gelatinase B) are strongly associated with malignant progression and matrix remodeling. These enzymes are a subject of intensive studies involving screening of comprehensive chemical libraries of synthetic inhibitors. There is no simple method available for measurement of activity of gelatinases and related MMPs. Here, we report a simple, inexpensive, and highly sensitive assay for MMP activity. The assay performed in a 96-well microtiter plate format employs biotin-labeled gelatin (denatured collagen type I) as a substrate. Following the substrate cleavage, only the proteolytic fragments bearing biotin moieties are captured by streptavidin coated on the plastic surface and the captured fragments with at least two biotin molecules should be revealed by streptavidin conjugated with horseradish peroxidase. The frequency of lysine residues is low in collagen type I relative to the MMP cleavage sequences (PXGX). Accordingly, the majority of the cleavage products must be devoid of biotin or possess only one biotin group. Both of these types of fragments cannot be recognized by the horseradish peroxidase-streptavidin conjugate. Therefore, higher gelatinolytic activity is associated with lower signal in the assay. This 2-h assay allows identification of gelatinolytic activity of MMP-2 in concentrations as low as 0.16 ng/ml. The sensitivity of this ELISA-like assay is comparable to that of gelatin zymography, a method widely used to detect gelatinases. However, in contrast to zymography, the assay directly measures the enzymatic activity of MMP samples. The gelatinolytic activity assay permits efficient analyses and screening of the MMP inhibitor panels and allows quantitation of gelatinolytic activity of various MMPs in solution as well as on cell surfaces. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11038285     DOI: 10.1006/abio.2000.4798

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  15 in total

1.  Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth.

Authors:  Albert G Remacle; Vladislav S Golubkov; Sergey A Shiryaev; Russell Dahl; John L Stebbins; Andrei V Chernov; Anton V Cheltsov; Maurizio Pellecchia; Alex Y Strongin
Journal:  Cancer Res       Date:  2012-03-09       Impact factor: 12.701

Review 2.  In vitro assays of angiogenesis for assessment of angiogenic and anti-angiogenic agents.

Authors:  Anne M Goodwin
Journal:  Microvasc Res       Date:  2007-06-06       Impact factor: 3.514

3.  The Wnt/planar cell polarity protein-tyrosine kinase-7 (PTK7) is a highly efficient proteolytic target of membrane type-1 matrix metalloproteinase: implications in cancer and embryogenesis.

Authors:  Vladislav S Golubkov; Alexei V Chekanov; Piotr Cieplak; Alexander E Aleshin; Andrei V Chernov; Wenhong Zhu; Ilian A Radichev; Danhua Zhang; P Duc Dong; Alex Y Strongin
Journal:  J Biol Chem       Date:  2010-09-13       Impact factor: 5.157

4.  Calprotectin inhibits matrix metalloproteinases by sequestration of zinc.

Authors:  B Isaksen; M K Fagerhol
Journal:  Mol Pathol       Date:  2001-10

5.  Reciprocal relationship between membrane type 1 matrix metalloproteinase and the algesic peptides of myelin basic protein contributes to chronic neuropathic pain.

Authors:  Sanghyun Hong; Albert G Remacle; Sergei A Shiryaev; Wonjun Choi; Swathi K Hullugundi; Jennifer Dolkas; Mila Angert; Tasuku Nishihara; Tony L Yaksh; Alex Y Strongin; Veronica I Shubayev
Journal:  Brain Behav Immun       Date:  2016-11-07       Impact factor: 7.217

6.  Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin.

Authors:  G N Marchenko; B I Ratnikov; D V Rozanov; A Godzik; E I Deryugina; A Y Strongin
Journal:  Biochem J       Date:  2001-06-15       Impact factor: 3.857

7.  Biochemical evidence of the interactions of membrane type-1 matrix metalloproteinase (MT1-MMP) with adenine nucleotide translocator (ANT): potential implications linking proteolysis with energy metabolism in cancer cells.

Authors:  Ilian A Radichev; Albert G Remacle; Nor Eddine Sounni; Sergey A Shiryaev; Dmitri V Rozanov; Wenhong Zhu; Natalya V Golubkova; Tatiana I Postnova; Vladislav S Golubkov; Alex Y Strongin
Journal:  Biochem J       Date:  2009-04-28       Impact factor: 3.857

8.  Matrix metalloproteinase-2-deficient fibroblasts exhibit an alteration in the fibrotic response to connective tissue growth factor/CCN2 because of an increase in the levels of endogenous fibronectin.

Authors:  Cristian A Droppelmann; Jaime Gutiérrez; Cecilia Vial; Enrique Brandan
Journal:  J Biol Chem       Date:  2009-03-09       Impact factor: 5.157

Review 9.  Targeting collagen for diagnostic imaging and therapeutic delivery.

Authors:  Hendra Wahyudi; Amanda A Reynolds; Yang Li; Shawn C Owen; S Michael Yu
Journal:  J Control Release       Date:  2016-01-07       Impact factor: 9.776

10.  Premalignant variations in extracellular matrix composition in chemically induced hepatocellular carcinoma in rats.

Authors:  Nabil M Abdel-Hamid
Journal:  J Membr Biol       Date:  2009-08-18       Impact factor: 1.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.